ABLE member Biocon Biologics expects the upcoming 12 months to be far more exciting than the recent past, led by a series of new biosimilar launches, including Aspart, Aflibercept and Denosumab.

Dr. Shreehas Tambe, MD & CEO, Biocon Biologics, said the financial impact of these recently launched products will begin to reflect significantly in the company's full-year numbers for fiscal year 2027.

Dr. Tambe’s comments at the recent BioAsia Conference was reported by CNBC-TV18.He said the company’s third quarter margins were in line with guidance. “We have said it will be in mid-20s, and we expect it to be 24 to 26%,” he said.

Dr. Tambe said competition in the insulin space is limited, primarily coming from the originator products. He stressed the importance of being a responsible player in chronic therapies, where long-term patient commitment is crucial. He pointed to the company's success with Glargine, which has captured a fifth of the US market, and stated that the company expects a similar trajectory for Aspart.

Dr. Tambe noted that new products typically take four to six quarters, or in some cases six to eight quarters, to reach their peak sales. He also highlighted the endurance of legacy products launched since 2018, which continue to deliver good margins and hold a quarter of the US market.

Contrary to the belief that the rise of GLP-1 drugs for diabetes and weight loss would diminish insulin demand, Dr Tambe observed a different trend. While acknowledging it is intuitive for pharmaceutical companies to redirect capacity towards more remunerative GLP-1s, he stated that insulin demand has not receded.

"We continue to see a very steady demand," Dr Tambe said, adding that there is even an "increasing demand for insulins." Given the limited competition, he believes this trend continues to present a "sizable opportunity" for Biocon Biologics.

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes.